Intellia Therapeutics moves HAE treatment closer to approval
statnews.com • • business
Key Points:
- Intellia Therapeutics reported that a single dose of its gene-editing treatment, lonvo-z, significantly reduced swelling attacks in patients with hereditary angioedema (HAE) during a Phase 3 trial.
- The therapy demonstrated an 87% reduction in attack rates compared to placebo, with over 60% of treated patients remaining attack-free, versus 11% in the placebo group.
- Lonvo-z, if approved, would be the second CRISPR-based medicine on the market and the first in vivo treatment that edits DNA directly within the patient's body.
- Intellia has already begun a rolling submission with regulatory agencies, moving closer to potential approval of this novel gene-editing therapy.
